Assessing the Reporting of Harms in Systematic Reviews Focused on the Therapeutic and Cosmetic Uses of Botulinum Toxin
- 10 January 2023
- journal article
- review article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 43 (2) , 85-95
Abstract
Background and Objective The expanding use of botulinum toxin (BoNT) in medical practice demonstrates the need to highlight whether there is adequate information regarding its safety profile. The aim of our study was to identify completeness of harms reporting for BoNT treatment within systematic reviews (SRs), assess quality of SRs using the AMSTAR-2 tool, and determine the degree of overlap among primary studies within each SR. Methods On May 31, 2022, we searched Embase, Epistemonikos, MEDLINE, and the Cochrane Database of Systematic Reviews for SRs on BoNT therapy. Screening and data extraction were performed in a masked, duplicate fashion. AMSTAR-2 was used to evaluate the methodological quality of included SRs. Corrected covered area (CCA) was calculated for SR dyads. Results Of the 90 included SRs, we found that 70 completed less than 50% of harms items. The most reported items were BoNT as a favorable intervention (73/90, 81.1%) and harms as a primary outcome (72/90, 80.0%). The least reported items were grades and severity scales used to classify harms (8/90, 8.9%) and number of treatment discontinuations in each arm (10/90, 11.1%). Eighty-three SRs were rated “critically low” (83/90, 92.2%), while 5 SRs were rated “high” (5/90, 5.6%) via AMSTAR-2 tool. Significant associations were found between completion of harms reporting and: (1) a “critically low” appraisal on AMSTAR-2 tool (p = 0.0060) and (2) whether harms was reported as a primary outcome (p = 0.0001). The total CCA overlap was determined to be 0.8%. Conclusion Our results demonstrate that harms are underreported within BoNT SRs. Because healthcare professionals often refer to SRs to guide clinical decision making, it is important to continue to explore shortcomings among BoNT literature in future studies.Keywords
This publication has 39 references indexed in Scilit:
- Side effects are incompletely reported among systematic reviews in gastroenterologyJournal of Clinical Epidemiology, 2015
- Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviewsBMJ, 2014
- Safety of Botulinum Toxin A in Aesthetic Treatments: A Systematic Review of Clinical StudiesDermatologic Surgery, 2014
- Advances in the use of botulinum neurotoxins in facial estheticsJournal of Cosmetic Dermatology, 2012
- Botulinum toxin type A in post-stroke upper limb spasticityCurrent Medical Research and Opinion, 2010
- Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting qualityPharmacoepidemiology and Drug Safety, 2009
- Poor reporting and inadequate searches were apparent in systematic reviews of adverse effectsJournal of Clinical Epidemiology, 2008
- Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a StrokeNew England Journal of Medicine, 2002
- Completeness of Safety Reporting in Randomized TrialsJAMA, 2001
- Botulinum toxin type A in the treatment of upper extremity spasticityNeurology, 1996